Autoimmune Hemolytic Anemia and Its Clinical Implication on Antiphospholipid Syndrome

NCT07743242 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2026-08-10

No results posted yet for this study

Summary

AIHA is a heterogeneous autoimmune cytopenia with variable severity and significant morbidity. APS is defined by thrombosis and/or obstetric morbidity with persistent antiphospholipid antibodies (aPL).

Conditions

  • Anti Phospholipid Syndrome

Interventions

DIAGNOSTIC_TEST

Hemoglobin

Blood sample

DIAGNOSTIC_TEST

Coombs test

Blood sample

Sponsors & Collaborators

  • New Valley University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-05
Primary Completion
2027-11-30
Completion
2028-04-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07743242 on ClinicalTrials.gov